| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transplantation Tolerance | 38 | 2023 | 617 | 7.590 |
Why?
|
| Kidney Transplantation | 104 | 2023 | 4251 | 7.520 |
Why?
|
| Transplantation Chimera | 40 | 2022 | 613 | 6.930 |
Why?
|
| Bone Marrow Transplantation | 42 | 2022 | 2765 | 4.790 |
Why?
|
| Graft Survival | 48 | 2023 | 3737 | 3.720 |
Why?
|
| Chimerism | 12 | 2023 | 158 | 3.630 |
Why?
|
| Transplantation Conditioning | 25 | 2022 | 1599 | 3.130 |
Why?
|
| Immune Tolerance | 32 | 2023 | 2259 | 2.890 |
Why?
|
| Graft Rejection | 50 | 2023 | 4397 | 2.860 |
Why?
|
| Macaca fascicularis | 48 | 2023 | 915 | 2.670 |
Why?
|
| HLA Antigens | 11 | 2019 | 1382 | 1.460 |
Why?
|
| Immunosuppressive Agents | 31 | 2022 | 4153 | 1.430 |
Why?
|
| Transplantation, Homologous | 38 | 2022 | 4777 | 1.310 |
Why?
|
| Kidney Failure, Chronic | 19 | 2021 | 2535 | 1.300 |
Why?
|
| Organ Transplantation | 10 | 2022 | 1140 | 1.220 |
Why?
|
| Histocompatibility Testing | 18 | 2020 | 741 | 1.140 |
Why?
|
| Islets of Langerhans Transplantation | 4 | 2019 | 745 | 1.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2023 | 5445 | 1.020 |
Why?
|
| Living Donors | 8 | 2021 | 621 | 1.010 |
Why?
|
| Isoantibodies | 12 | 2020 | 679 | 0.940 |
Why?
|
| Primates | 9 | 2023 | 545 | 0.910 |
Why?
|
| Immunologic Memory | 8 | 2017 | 1348 | 0.850 |
Why?
|
| Histocompatibility | 4 | 2018 | 330 | 0.810 |
Why?
|
| Kidney | 18 | 2023 | 7184 | 0.750 |
Why?
|
| Liver Transplantation | 16 | 2023 | 2119 | 0.740 |
Why?
|
| Antibodies, Monoclonal | 15 | 2023 | 9274 | 0.640 |
Why?
|
| CD40 Ligand | 6 | 2023 | 526 | 0.620 |
Why?
|
| Tissue Donors | 12 | 2022 | 2241 | 0.610 |
Why?
|
| Major Histocompatibility Complex | 10 | 2020 | 936 | 0.610 |
Why?
|
| Nephrectomy | 4 | 2012 | 1050 | 0.600 |
Why?
|
| Interleukin-2 | 3 | 2015 | 1904 | 0.590 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2019 | 2988 | 0.560 |
Why?
|
| Transplantation Immunology | 4 | 2015 | 546 | 0.550 |
Why?
|
| Renal Dialysis | 9 | 2022 | 1783 | 0.540 |
Why?
|
| Animals | 89 | 2023 | 168768 | 0.530 |
Why?
|
| Hypertension | 6 | 2016 | 8479 | 0.500 |
Why?
|
| Transplantation, Heterologous | 11 | 2023 | 2383 | 0.490 |
Why?
|
| Hand-Assisted Laparoscopy | 1 | 2012 | 16 | 0.440 |
Why?
|
| T-Lymphocytes | 15 | 2015 | 10183 | 0.420 |
Why?
|
| Ultrasonography, Doppler | 2 | 2011 | 458 | 0.410 |
Why?
|
| Hematopoiesis | 2 | 2019 | 2073 | 0.410 |
Why?
|
| Adaptation, Physiological | 2 | 2010 | 1312 | 0.410 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2022 | 549 | 0.410 |
Why?
|
| Models, Animal | 8 | 2019 | 2173 | 0.410 |
Why?
|
| Immunotoxins | 1 | 2012 | 179 | 0.400 |
Why?
|
| Polytetrafluoroethylene | 2 | 2011 | 233 | 0.390 |
Why?
|
| Vascular Resistance | 2 | 2011 | 936 | 0.390 |
Why?
|
| Diphtheria Toxin | 1 | 2012 | 255 | 0.390 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2022 | 277 | 0.390 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2018 | 4479 | 0.390 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 1620 | 0.350 |
Why?
|
| Stem Cell Factor | 1 | 2010 | 219 | 0.350 |
Why?
|
| Antilymphocyte Serum | 8 | 2015 | 492 | 0.340 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 227 | 0.330 |
Why?
|
| Brain Death | 5 | 2023 | 348 | 0.330 |
Why?
|
| Carotid Arteries | 1 | 2013 | 950 | 0.330 |
Why?
|
| Lymphocele | 1 | 2008 | 16 | 0.330 |
Why?
|
| Multiple Myeloma | 4 | 2019 | 5181 | 0.320 |
Why?
|
| Killer Cells, Natural | 2 | 2012 | 2133 | 0.320 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2013 | 3773 | 0.320 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2011 | 934 | 0.310 |
Why?
|
| Kidney Diseases | 4 | 2014 | 2148 | 0.300 |
Why?
|
| Islets of Langerhans | 5 | 2003 | 1352 | 0.300 |
Why?
|
| Histocompatibility Antigens | 2 | 2020 | 471 | 0.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 648 | 0.290 |
Why?
|
| Swine | 8 | 2023 | 5918 | 0.290 |
Why?
|
| Splenectomy | 8 | 2010 | 395 | 0.280 |
Why?
|
| Uric Acid | 1 | 2012 | 766 | 0.280 |
Why?
|
| RNA, Messenger | 3 | 2019 | 13035 | 0.270 |
Why?
|
| Whole-Body Irradiation | 9 | 2009 | 449 | 0.270 |
Why?
|
| Carotid Stenosis | 1 | 2013 | 854 | 0.270 |
Why?
|
| Cyclosporine | 8 | 2015 | 788 | 0.260 |
Why?
|
| Graft vs Host Disease | 2 | 2017 | 2958 | 0.260 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 369 | 0.250 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 804 | 0.250 |
Why?
|
| Humans | 104 | 2023 | 744366 | 0.250 |
Why?
|
| Vascular Patency | 5 | 2022 | 887 | 0.250 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 39052 | 0.240 |
Why?
|
| Male | 76 | 2023 | 350115 | 0.240 |
Why?
|
| Liver Failure, Acute | 2 | 2018 | 165 | 0.230 |
Why?
|
| Lymphatic Vessels | 1 | 2008 | 353 | 0.230 |
Why?
|
| Brachial Artery | 2 | 2017 | 369 | 0.230 |
Why?
|
| Lymphocyte Depletion | 8 | 2010 | 608 | 0.220 |
Why?
|
| Transplantation | 2 | 1995 | 217 | 0.220 |
Why?
|
| Neutropenia | 1 | 2008 | 895 | 0.220 |
Why?
|
| Genes, bcl-2 | 1 | 2023 | 122 | 0.220 |
Why?
|
| Time Factors | 21 | 2019 | 40075 | 0.220 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2015 | 3390 | 0.220 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 2242 | 0.210 |
Why?
|
| Tissue and Organ Procurement | 5 | 2021 | 896 | 0.210 |
Why?
|
| Radiographic Image Enhancement | 1 | 2007 | 885 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 2214 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2017 | 6539 | 0.210 |
Why?
|
| Cell Separation | 3 | 2003 | 1751 | 0.210 |
Why?
|
| Clinical Protocols | 2 | 2020 | 1461 | 0.200 |
Why?
|
| Kidney Function Tests | 4 | 2015 | 683 | 0.200 |
Why?
|
| Postoperative Complications | 13 | 2019 | 15297 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 4 | 2015 | 2166 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 4386 | 0.190 |
Why?
|
| Renin | 1 | 2023 | 642 | 0.190 |
Why?
|
| Skin Transplantation | 3 | 2020 | 1074 | 0.190 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 7914 | 0.190 |
Why?
|
| User-Computer Interface | 1 | 2007 | 1431 | 0.180 |
Why?
|
| Lung Transplantation | 3 | 2015 | 1155 | 0.180 |
Why?
|
| End Stage Liver Disease | 2 | 2023 | 314 | 0.180 |
Why?
|
| Cyclosporins | 9 | 1990 | 220 | 0.180 |
Why?
|
| Animals, Genetically Modified | 2 | 2023 | 1549 | 0.180 |
Why?
|
| Expert Testimony | 1 | 2022 | 356 | 0.170 |
Why?
|
| Immunologic Techniques | 1 | 1999 | 219 | 0.170 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 157 | 0.170 |
Why?
|
| Japan | 5 | 2016 | 1360 | 0.170 |
Why?
|
| Blood Pressure | 2 | 2011 | 8551 | 0.170 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 4253 | 0.170 |
Why?
|
| Heat Stroke | 1 | 2018 | 31 | 0.160 |
Why?
|
| Stroke | 4 | 2014 | 9981 | 0.160 |
Why?
|
| Middle Aged | 36 | 2021 | 213390 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2003 | 1115 | 0.160 |
Why?
|
| Atherosclerosis | 2 | 2013 | 3444 | 0.160 |
Why?
|
| Retrospective Studies | 23 | 2023 | 77460 | 0.160 |
Why?
|
| Renal Circulation | 3 | 2011 | 334 | 0.160 |
Why?
|
| Thromboembolism | 2 | 2004 | 987 | 0.150 |
Why?
|
| ABO Blood-Group System | 5 | 2009 | 367 | 0.150 |
Why?
|
| Female | 51 | 2023 | 380193 | 0.150 |
Why?
|
| Isoantigens | 3 | 2015 | 567 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 1613 | 0.150 |
Why?
|
| B-Lymphocytes | 4 | 2017 | 4666 | 0.150 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 104 | 0.150 |
Why?
|
| Pancreas Transplantation | 3 | 1995 | 187 | 0.150 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 15160 | 0.140 |
Why?
|
| Liver | 8 | 2022 | 7475 | 0.140 |
Why?
|
| Haplorhini | 3 | 2009 | 552 | 0.140 |
Why?
|
| Flow Cytometry | 8 | 2012 | 5974 | 0.140 |
Why?
|
| Liver Failure | 1 | 2018 | 241 | 0.140 |
Why?
|
| Treatment Outcome | 18 | 2022 | 63107 | 0.140 |
Why?
|
| Immunoglobulin G | 5 | 2023 | 4561 | 0.140 |
Why?
|
| Delayed Graft Function | 2 | 2012 | 48 | 0.130 |
Why?
|
| Research Report | 1 | 2018 | 355 | 0.130 |
Why?
|
| Radial Artery | 1 | 2017 | 194 | 0.130 |
Why?
|
| Clonal Deletion | 1 | 2015 | 79 | 0.130 |
Why?
|
| Vascular Diseases | 2 | 2022 | 1161 | 0.130 |
Why?
|
| Heart Transplantation | 4 | 2002 | 3112 | 0.130 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2015 | 53 | 0.120 |
Why?
|
| Bone Marrow | 4 | 2020 | 2948 | 0.120 |
Why?
|
| Thymus Gland | 4 | 2007 | 1267 | 0.120 |
Why?
|
| Death | 2 | 2010 | 678 | 0.120 |
Why?
|
| Creatinine | 6 | 2012 | 1919 | 0.120 |
Why?
|
| Lymphocyte Transfusion | 1 | 2015 | 236 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1200 | 0.120 |
Why?
|
| Mice | 11 | 2022 | 81201 | 0.120 |
Why?
|
| Risk Factors | 11 | 2023 | 72296 | 0.120 |
Why?
|
| Adult | 36 | 2023 | 214052 | 0.120 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2013 | 22 | 0.120 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 154 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 15078 | 0.110 |
Why?
|
| Th1 Cells | 1 | 2018 | 1057 | 0.110 |
Why?
|
| Ureterostomy | 1 | 2012 | 17 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2014 | 535 | 0.110 |
Why?
|
| Angioplasty, Balloon | 1 | 2017 | 653 | 0.110 |
Why?
|
| Cystostomy | 1 | 2012 | 26 | 0.110 |
Why?
|
| Veins | 1 | 2017 | 770 | 0.110 |
Why?
|
| Catheters, Indwelling | 1 | 2015 | 426 | 0.110 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 272 | 0.110 |
Why?
|
| Hepatitis C | 3 | 2020 | 1591 | 0.110 |
Why?
|
| Protein S Deficiency | 1 | 2011 | 16 | 0.110 |
Why?
|
| Hypertension, Malignant | 1 | 2012 | 19 | 0.100 |
Why?
|
| Genotype | 2 | 2019 | 12952 | 0.100 |
Why?
|
| Immunoconjugates | 1 | 1999 | 901 | 0.100 |
Why?
|
| Myeloablative Agonists | 1 | 2013 | 218 | 0.100 |
Why?
|
| Survival Rate | 6 | 2013 | 12788 | 0.100 |
Why?
|
| Muromonab-CD3 | 2 | 1996 | 96 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2000 | 3771 | 0.100 |
Why?
|
| Upper Extremity | 1 | 2017 | 648 | 0.100 |
Why?
|
| Mannose | 5 | 1990 | 124 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 2007 | 0.100 |
Why?
|
| Capillary Leak Syndrome | 1 | 2011 | 31 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 1031 | 0.100 |
Why?
|
| Aged | 16 | 2019 | 163288 | 0.100 |
Why?
|
| Interleukin-15 | 1 | 2012 | 184 | 0.100 |
Why?
|
| Prognosis | 5 | 2020 | 29060 | 0.100 |
Why?
|
| Learning Curve | 1 | 2012 | 208 | 0.100 |
Why?
|
| Portal Vein | 1 | 2013 | 437 | 0.090 |
Why?
|
| Cattle | 2 | 2015 | 3922 | 0.090 |
Why?
|
| C-Peptide | 2 | 2003 | 419 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2011 | 1588 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6489 | 0.090 |
Why?
|
| 4-Aminobenzoic Acid | 5 | 1990 | 22 | 0.090 |
Why?
|
| Leukapheresis | 1 | 2010 | 131 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2015 | 2008 | 0.090 |
Why?
|
| Ankle | 1 | 2012 | 327 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2023 | 53290 | 0.090 |
Why?
|
| Ureter | 1 | 2012 | 375 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2017 | 2540 | 0.090 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2011 | 236 | 0.090 |
Why?
|
| Blood Substitutes | 4 | 1992 | 58 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 633 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13693 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2015 | 1534 | 0.080 |
Why?
|
| Cadaver | 2 | 2008 | 1337 | 0.080 |
Why?
|
| Proteinuria | 1 | 2011 | 658 | 0.080 |
Why?
|
| Lymphatic Irradiation | 1 | 2008 | 103 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2012 | 662 | 0.080 |
Why?
|
| Biopsy | 4 | 2008 | 6755 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3589 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 6896 | 0.080 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 1423 | 0.080 |
Why?
|
| Blood Coagulation Disorders | 2 | 2000 | 337 | 0.070 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 170 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1832 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 18034 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2015 | 2740 | 0.070 |
Why?
|
| Arteriosclerosis | 1 | 2011 | 1092 | 0.070 |
Why?
|
| Longevity | 1 | 2014 | 1071 | 0.070 |
Why?
|
| Granzymes | 1 | 2008 | 271 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 3 | 2017 | 820 | 0.070 |
Why?
|
| Blood Group Incompatibility | 2 | 1998 | 146 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2012 | 1301 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2013 | 40559 | 0.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 1391 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 2513 | 0.070 |
Why?
|
| Nephritis, Hereditary | 1 | 2006 | 88 | 0.070 |
Why?
|
| Thrombolytic Therapy | 1 | 2015 | 2162 | 0.070 |
Why?
|
| Biocompatible Materials | 2 | 2011 | 1736 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 2158 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 2006 | 183 | 0.060 |
Why?
|
| Postoperative Care | 1 | 1992 | 1487 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2013 | 3207 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 2015 | 518 | 0.060 |
Why?
|
| ROC Curve | 1 | 2012 | 3528 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2017 | 10483 | 0.060 |
Why?
|
| Tissue Preservation | 3 | 1992 | 182 | 0.060 |
Why?
|
| Haplotypes | 1 | 2011 | 2779 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2015 | 1887 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 844 | 0.060 |
Why?
|
| Swine, Miniature | 2 | 2023 | 961 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 20130 | 0.060 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 1968 | 0.060 |
Why?
|
| Aging | 2 | 2016 | 8664 | 0.060 |
Why?
|
| Blood Vessels | 2 | 1999 | 1125 | 0.060 |
Why?
|
| Age Factors | 3 | 2016 | 18373 | 0.060 |
Why?
|
| Hepatic Encephalopathy | 2 | 2012 | 139 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 1392 | 0.060 |
Why?
|
| Asia | 2 | 1995 | 609 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1996 | 595 | 0.060 |
Why?
|
| Disaccharides | 1 | 2003 | 171 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12356 | 0.060 |
Why?
|
| Serum Albumin, Bovine | 1 | 2003 | 324 | 0.050 |
Why?
|
| Radiology Information Systems | 1 | 2007 | 523 | 0.050 |
Why?
|
| Chimera | 3 | 1999 | 485 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2011 | 6366 | 0.050 |
Why?
|
| Preoperative Care | 1 | 1992 | 2251 | 0.050 |
Why?
|
| Drainage | 1 | 2008 | 1142 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3611 | 0.050 |
Why?
|
| Registries | 2 | 2014 | 8091 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 2047 | 0.050 |
Why?
|
| Organ Preservation | 5 | 1997 | 331 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2012 | 2585 | 0.050 |
Why?
|
| Intestine, Small | 3 | 1992 | 1240 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2004 | 305 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 8642 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2009 | 3476 | 0.050 |
Why?
|
| Cytokines | 1 | 2015 | 7323 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 1184 | 0.050 |
Why?
|
| Patient Selection | 3 | 2022 | 4216 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 1956 | 0.050 |
Why?
|
| Transgenes | 1 | 2023 | 1009 | 0.040 |
Why?
|
| Plasmapheresis | 2 | 1998 | 211 | 0.040 |
Why?
|
| Thrombosis | 3 | 2000 | 2968 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2020 | 448 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 10943 | 0.040 |
Why?
|
| Boston | 3 | 2017 | 9312 | 0.040 |
Why?
|
| Prostaglandins | 3 | 1989 | 405 | 0.040 |
Why?
|
| Hepatectomy | 2 | 2020 | 550 | 0.040 |
Why?
|
| Laparoscopy | 2 | 2009 | 2150 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 13286 | 0.040 |
Why?
|
| Alprostadil | 2 | 2004 | 89 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2020 | 613 | 0.040 |
Why?
|
| Hemoglobins | 3 | 1992 | 1532 | 0.040 |
Why?
|
| Horses | 2 | 2015 | 304 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2008 | 1860 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 1107 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 6386 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 524 | 0.040 |
Why?
|
| Cognition | 1 | 2016 | 6770 | 0.040 |
Why?
|
| Child | 11 | 2022 | 77709 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2023 | 764 | 0.040 |
Why?
|
| Stents | 2 | 2022 | 3282 | 0.040 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2017 | 57 | 0.040 |
Why?
|
| Antibodies | 2 | 2022 | 2460 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2003 | 6254 | 0.040 |
Why?
|
| Antibody Formation | 3 | 1997 | 1402 | 0.040 |
Why?
|
| Incidence | 2 | 2014 | 20952 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2008 | 2063 | 0.040 |
Why?
|
| Spleen | 1 | 2003 | 2362 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2012 | 4687 | 0.040 |
Why?
|
| Dogs | 6 | 1992 | 3912 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2023 | 1059 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 5749 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3255 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2000 | 674 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 1999 | 927 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 9240 | 0.030 |
Why?
|
| Prevalence | 1 | 2013 | 15221 | 0.030 |
Why?
|
| Lymphocyte Activation | 2 | 1999 | 5524 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2003 | 3689 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 13991 | 0.030 |
Why?
|
| Antiviral Agents | 2 | 2020 | 2987 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2002 | 570 | 0.030 |
Why?
|
| Neutrophils | 1 | 2008 | 3721 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 1997 | 1035 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2017 | 19233 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 793 | 0.030 |
Why?
|
| Adolescent | 14 | 2014 | 85779 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 15520 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2014 | 6486 | 0.030 |
Why?
|
| Polyethylene Glycols | 2 | 1992 | 1182 | 0.030 |
Why?
|
| Survival Analysis | 2 | 1999 | 10252 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 149 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2000 | 1127 | 0.030 |
Why?
|
| Papio | 3 | 2003 | 656 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8319 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2007 | 3208 | 0.030 |
Why?
|
| Chronic Disease | 5 | 2011 | 9145 | 0.030 |
Why?
|
| Thromboxane B2 | 2 | 1991 | 152 | 0.030 |
Why?
|
| Comorbidity | 2 | 2021 | 10388 | 0.030 |
Why?
|
| Phlebography | 1 | 2015 | 333 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2015 | 667 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2007 | 4026 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 29786 | 0.030 |
Why?
|
| Family | 2 | 1995 | 3147 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 199 | 0.030 |
Why?
|
| Young Adult | 3 | 2014 | 56429 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1997 | 357 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2015 | 225 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 3873 | 0.030 |
Why?
|
| Hospitals, General | 1 | 2017 | 749 | 0.030 |
Why?
|
| Oxalates | 1 | 2013 | 105 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 1997 | 6171 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1996 | 743 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2020 | 1379 | 0.030 |
Why?
|
| Epoprostenol | 3 | 1988 | 254 | 0.030 |
Why?
|
| Protein S | 1 | 2011 | 30 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14723 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1996 | 895 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 2011 | 223 | 0.030 |
Why?
|
| Organ Preservation Solutions | 1 | 1992 | 98 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2011 | 66 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1991 | 83 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 705 | 0.020 |
Why?
|
| Rats, Inbred Lew | 4 | 1996 | 1162 | 0.020 |
Why?
|
| Rats, Inbred Strains | 5 | 1990 | 2186 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 128 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2023 | 3486 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 354 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1991 | 309 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2124 | 0.020 |
Why?
|
| Device Removal | 1 | 2015 | 656 | 0.020 |
Why?
|
| Parathyroidectomy | 1 | 1992 | 235 | 0.020 |
Why?
|
| Lymphatic System | 1 | 1991 | 252 | 0.020 |
Why?
|
| Insulin | 3 | 2001 | 6582 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 1997 | 0.020 |
Why?
|
| Intracranial Pressure | 1 | 2012 | 326 | 0.020 |
Why?
|
| Intracranial Hypertension | 1 | 2012 | 186 | 0.020 |
Why?
|
| Polyurethanes | 1 | 1989 | 107 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 11366 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3508 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2016 | 1184 | 0.020 |
Why?
|
| Complement C4b | 1 | 2009 | 135 | 0.020 |
Why?
|
| Hepatitis Viruses | 1 | 1988 | 17 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 11726 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1988 | 43 | 0.020 |
Why?
|
| Walking | 1 | 2016 | 1180 | 0.020 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1992 | 300 | 0.020 |
Why?
|
| International Cooperation | 1 | 1995 | 1420 | 0.020 |
Why?
|
| Europe | 1 | 1995 | 3338 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2014 | 2634 | 0.020 |
Why?
|
| Thromboxane-A Synthase | 1 | 1987 | 35 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 1992 | 767 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 1994 | 2377 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 1341 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1991 | 798 | 0.020 |
Why?
|
| Gabexate | 1 | 1987 | 12 | 0.020 |
Why?
|
| Acrylates | 1 | 1987 | 89 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 3587 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 412 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 411 | 0.020 |
Why?
|
| alpha-Cyclodextrins | 1 | 1987 | 11 | 0.020 |
Why?
|
| Pyridoxal Phosphate | 1 | 1987 | 127 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2017 | 2926 | 0.020 |
Why?
|
| Methacrylates | 1 | 1987 | 107 | 0.020 |
Why?
|
| Acute Disease | 3 | 2002 | 7147 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 1880 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 57776 | 0.020 |
Why?
|
| Rats | 9 | 1996 | 24252 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 455 | 0.020 |
Why?
|
| Methylprednisolone | 3 | 1996 | 387 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1993 | 1821 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 1992 | 984 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 341 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 15535 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 957 | 0.020 |
Why?
|
| Portal System | 2 | 1997 | 52 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 3177 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 2649 | 0.020 |
Why?
|
| Ketorolac Tromethamine | 1 | 2004 | 21 | 0.020 |
Why?
|
| Logistic Models | 2 | 2016 | 13409 | 0.020 |
Why?
|
| Phosphates | 1 | 1987 | 785 | 0.010 |
Why?
|
| Immune System | 1 | 2009 | 806 | 0.010 |
Why?
|
| Angiography | 1 | 2009 | 1639 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2014 | 2725 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 1170 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 3966 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2016 | 9849 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2011 | 23404 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 2861 | 0.010 |
Why?
|
| Guanidines | 2 | 1997 | 193 | 0.010 |
Why?
|
| RNA, Nuclear | 1 | 2002 | 30 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 21833 | 0.010 |
Why?
|
| Regeneration | 1 | 1991 | 1485 | 0.010 |
Why?
|
| Reoperation | 1 | 2012 | 4201 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 2700 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 2 | 1994 | 418 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 1996 | 3338 | 0.010 |
Why?
|
| Ticlopidine | 1 | 1987 | 899 | 0.010 |
Why?
|
| Urinary Tract Infections | 1 | 1988 | 788 | 0.010 |
Why?
|
| RNA, Viral | 2 | 2002 | 2901 | 0.010 |
Why?
|
| Perfusion | 3 | 1992 | 1360 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7730 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1988 | 1178 | 0.010 |
Why?
|
| Liver Function Tests | 2 | 1994 | 528 | 0.010 |
Why?
|
| Phenotype | 1 | 2017 | 16367 | 0.010 |
Why?
|
| Glucose Tolerance Test | 2 | 1996 | 1151 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1837 | 0.010 |
Why?
|
| Syndrome | 1 | 1996 | 3252 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2014 | 6542 | 0.010 |
Why?
|
| Smoking | 1 | 2016 | 8987 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 1739 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2010 | 2029 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 1958 | 0.010 |
Why?
|
| Immunosorbents | 1 | 1998 | 22 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 1950 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1998 | 158 | 0.010 |
Why?
|
| Diet | 1 | 2016 | 7937 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1998 | 370 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1992 | 1681 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2002 | 1041 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1992 | 6077 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2009 | 5096 | 0.010 |
Why?
|
| Pancytopenia | 1 | 1997 | 104 | 0.010 |
Why?
|
| Heparin | 1 | 2004 | 1637 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 335 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 9857 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1988 | 2134 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 6621 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1997 | 349 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1997 | 374 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 11031 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1988 | 2104 | 0.010 |
Why?
|
| Transplants | 1 | 1998 | 209 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10637 | 0.010 |
Why?
|
| Brain | 1 | 2022 | 26388 | 0.010 |
Why?
|
| Pregnancy | 1 | 1997 | 29144 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 1997 | 226 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 16000 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 5388 | 0.010 |
Why?
|
| Fluorescence | 1 | 1997 | 751 | 0.010 |
Why?
|
| Tissue Distribution | 2 | 1989 | 2327 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1996 | 645 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1998 | 1005 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1997 | 697 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1996 | 1386 | 0.010 |
Why?
|
| Fathers | 1 | 1997 | 358 | 0.010 |
Why?
|
| Puerperal Disorders | 1 | 1997 | 275 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1994 | 349 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1994 | 424 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 1856 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 17446 | 0.010 |
Why?
|
| Maltose | 1 | 1992 | 34 | 0.010 |
Why?
|
| Child, Preschool | 4 | 1997 | 41005 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1992 | 186 | 0.010 |
Why?
|
| Raffinose | 1 | 1992 | 52 | 0.010 |
Why?
|
| Hypertonic Solutions | 1 | 1992 | 93 | 0.010 |
Why?
|
| Reference Values | 2 | 1990 | 4982 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1997 | 1842 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2560 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2891 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1993 | 455 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1992 | 212 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1996 | 1537 | 0.010 |
Why?
|
| Solutions | 1 | 1992 | 426 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 3070 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1992 | 420 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1993 | 841 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1993 | 1095 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1996 | 1641 | 0.010 |
Why?
|
| Mesentery | 1 | 1991 | 205 | 0.010 |
Why?
|
| Lymphography | 1 | 1991 | 201 | 0.010 |
Why?
|
| Allopurinol | 1 | 1992 | 191 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 1997 | 1530 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1996 | 1607 | 0.010 |
Why?
|
| Pancreatic Extracts | 1 | 1989 | 5 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 4894 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1996 | 2227 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 1992 | 527 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1992 | 675 | 0.010 |
Why?
|
| Glutathione | 1 | 1992 | 590 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1993 | 1369 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1992 | 1525 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 4600 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 12073 | 0.010 |
Why?
|
| Thromboxane A2 | 1 | 1988 | 93 | 0.000 |
Why?
|
| Sugar Phosphates | 1 | 1987 | 43 | 0.000 |
Why?
|
| Leukocytes | 1 | 1996 | 2045 | 0.000 |
Why?
|
| Pan troglodytes | 1 | 1988 | 229 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1989 | 963 | 0.000 |
Why?
|
| Adenine Nucleotides | 1 | 1987 | 121 | 0.000 |
Why?
|
| Guanosine Triphosphate | 1 | 1988 | 321 | 0.000 |
Why?
|
| Plasma Exchange | 1 | 1988 | 152 | 0.000 |
Why?
|
| Benzamidines | 1 | 1987 | 25 | 0.000 |
Why?
|
| Phosphorylcholine | 1 | 1987 | 162 | 0.000 |
Why?
|
| United States | 1 | 1995 | 69872 | 0.000 |
Why?
|
| Cyclodextrins | 1 | 1987 | 57 | 0.000 |
Why?
|
| Adenosine | 1 | 1992 | 825 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1996 | 2455 | 0.000 |
Why?
|
| Azathioprine | 1 | 1988 | 354 | 0.000 |
Why?
|
| Bilirubin | 1 | 1988 | 425 | 0.000 |
Why?
|
| Urine | 1 | 1988 | 370 | 0.000 |
Why?
|
| Mothers | 1 | 1997 | 2165 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1996 | 6459 | 0.000 |
Why?
|
| Esters | 1 | 1987 | 210 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1994 | 2617 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 2505 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1988 | 592 | 0.000 |
Why?
|
| Catheterization, Central Venous | 1 | 1989 | 514 | 0.000 |
Why?
|
| Cold Temperature | 1 | 1988 | 772 | 0.000 |
Why?
|
| Base Sequence | 1 | 1996 | 12797 | 0.000 |
Why?
|
| Microcirculation | 1 | 1989 | 1287 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1989 | 1460 | 0.000 |
Why?
|
| NAD | 1 | 1987 | 590 | 0.000 |
Why?
|
| Atrophy | 1 | 1988 | 1584 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1988 | 1124 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 18111 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1989 | 2027 | 0.000 |
Why?
|
| Temperature | 1 | 1987 | 2204 | 0.000 |
Why?
|
| Virus Replication | 1 | 1988 | 2535 | 0.000 |
Why?
|
| Mitochondria | 1 | 1992 | 3514 | 0.000 |
Why?
|
| Cholesterol | 1 | 1988 | 2919 | 0.000 |
Why?
|
| Ischemia | 1 | 1987 | 1907 | 0.000 |
Why?
|
| Weight Gain | 1 | 1989 | 2293 | 0.000 |
Why?
|
| Body Weight | 1 | 1989 | 4671 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1987 | 3759 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1987 | 2897 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1987 | 2509 | 0.000 |
Why?
|
| Infant | 1 | 1997 | 35134 | 0.000 |
Why?
|